Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ma ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.